US05370A1088
© PR Newswire
03.02.2026
RNA
LISTED
NASDAQ
Avidity Biosciences Announces Expected Record Date for Spin-Off
News Preview
SAN DIEGO, Feb. 2, 2026 /PRNewswire/ -- Avidity Biosciences, Inc. ("Avidity") (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates ("AOCs™") to profoundly improve people's lives, today announced that its board of directors has designated the close of business,...
Themefolio
Profiler
Peergroup
© PR Newswire
19.11.2025
RNA
LISTED
NASDAQ
Avidity Biosciences Announces U.S. Managed Access Program (MAP) for Investigational Therapy del-zota in DMD44
News Preview
SAN DIEGO, Nov. 19, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced its Managed Access Program (MAP) for investigational therapy delpacibart zotadir...
Themefolio
Profiler
Peergroup
© PR Newswire
10.11.2025
RNA
LISTED
NASDAQ
Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights
News Preview
Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology programs into a new public company ("SpinCo")
Clear path forward aligned with FDA following pre-...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© BusinessWire
28.10.2025
RNA
LISTED
NASDAQ
RNA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Avidity Biosciences, Inc. Is Fair to Shareholders
News Preview
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Avidity Biosciences, Inc. (NASDAQ: RNA) to Novartis for $72.00 per share in cash is fair to Avidity shareholders.
Halper Sadeh encourages Avidity shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halp...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
23.01.2026
© BusinessWire
28.10.2025
RNA
LISTED
NASDAQ
Avidity Biosciences Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Avidity Biosciences, Inc. - RNA
News Preview
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Avidity Biosciences, Inc. (NasdaqGM: RNA) to Novartis AG. Under the terms of the proposed transaction, shareholders of Avidity will receive $72.00 in cash for each share of Avidity that they...
Themefolio
Profiler
Peergroup
© PR Newswire
26.10.2025
RNA
LISTED
NASDAQ
Avidity Biosciences Enters into Agreement to be Acquired by Novartis AG
News Preview
Novartis to acquire Avidity
for USD 72.00 per share in cash for total equity value of approximately USD 12.0 billion
Avidity expects to separate its early-stage precision cardiology programs
into a new company ("SpinCo")...
Themefolio
Profiler
Peergroup
© PR Newswire
16.10.2025
RNA
LISTED
NASDAQ
Avidity Biosciences to Participate in Upcoming Investor Conference
News Preview
SAN DIEGO, Oct. 16, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will participate in a panel discussion at the following...
Themefolio
Profiler
Peergroup
© PR Newswire
13.10.2025
RNA
LISTED
NASDAQ
Avidity Biosciences Announces Positive Pre-BLA Meeting with U.S. FDA for del-zota in DMD44 with a Submission Planned for Q1 2026
News Preview
SAN DIEGO, Oct. 13, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™) to profoundly improve people's lives, today announced that the Company completed a positive pre-B...
Themefolio
Profiler
Peergroup
© PR Newswire
06.10.2025
RNA
LISTED
NASDAQ
Avidity Biosciences to Present Data from EXPLORE44® Clinical Development Program of Del-Zota in DMD44 at 30th Annual Congress of the World Muscle Society
News Preview
SAN DIEGO, Oct. 6, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™) to profoundly improve people's lives, today announced that it will deliver late-breaking oral and...
Themefolio
Profiler
Peergroup
© PR Newswire
15.09.2025
RNA
LISTED
NASDAQ
Avidity Biosciences, Inc. Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
News Preview
SAN DIEGO, Sept. 15, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that it has closed its previously announced underwritten public offering of 17,250,000 shares of its common stock...
Themefolio
Profiler
Peergroup
© PR Newswire
10.09.2025
RNA
LISTED
NASDAQ
Avidity Biosciences Announces Proposed Public Offering of Common Stock
News Preview
SAN DIEGO, Sept. 10, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that it intends to offer and sell, subject to market and other conditions, $500.0 million of shares of its common...
Themefolio
Profiler
Peergroup
© PR Newswire
10.09.2025
RNA
LISTED
NASDAQ
Avidity Biosciences' Del-zota Demonstrated Reversal of Disease Progression Across Key Functional Endpoints in EXPLORE44® and EXPLORE44-OLE™ Phase 1/2 Trial in People Living with DMD44
News Preview
-- Unprecedented improvement compared to baseline and natural history in multiple functional measures including Time to Rise from Floor (TTR), 4-Stair Climb (4SC), Performance of Upper Limb (PUL) and 10-Meter Walk/Run Test (10mWRT) at approximately one year --
-- Unprecedented rapid reduction in creatine kinase (CK) to near normal levels maintain...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© PR Newswire
27.08.2025
RNA
LISTED
NASDAQ
Avidity Biosciences to Participate in Upcoming Investor Conferences
News Preview
SAN DIEGO, Aug. 27, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will participate in a fireside chat during the following investor conferences:...
Themefolio
Profiler
Peergroup
© PR Newswire
28.07.2025
RNA
LISTED
NASDAQ
Avidity Biosciences Announces Completion of Enrollment for HARBOR™, the First Global Phase 3 Trial of Delpacibart Etedesiran (del-desiran) for Treatment of DM1 and Provides Guidance on Regulatory Submission
News Preview
-- Topline data readout from HARBOR study anticipated in Q2 2026 ---- Marketing application submissions for del-desiran including in U.S., EU and Japan anticipated to start in H2 2026; on track to potentially be the first globally approved drug for DM1---- On track to share updates from ongoing MARINA-OLE™ trial of del-desiran including long-term...
Themefolio
Profiler
Peergroup
© PR Newswire
23.07.2025
RNA
LISTED
NASDAQ
Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Zotadirsen (del-zota) for the Treatment of DMD in People with Mutations Amenable to Exon 44 Skipping
News Preview
-- On track for planned BLA submission for del-zota at year end 2025 --
SAN DIEGO, July 23, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that the U.S. Food and Drug Administration...
Themefolio
Profiler
Peergroup
© PR Newswire
11.06.2025
RNA
LISTED
NASDAQ
Avidity Biosciences to Present Topline Data from Phase 1/2 FORTITUDE™ Trial of Del-brax in People Living with Facioscapulohumeral Muscular Dystrophy at 32nd Annual FSHD Society International Research Congress
News Preview
-- FDA alignment on accelerated and full approval pathways for delpacibart braxlosiran (del-brax) in facioscapulohumeral muscular dystrophy (FSHD) --
-- Jeffrey M. Statland, M.D., Professor of Neurology, University of Kansas Medical Center, and FORTITUDE trial investigator, will present topline del-brax data from dose escalation cohorts in oral p...
Themefolio
Profiler
Peergroup
© PR Newswire
09.06.2025
RNA
LISTED
NASDAQ
Avidity Biosciences Announces Positive Topline Phase 1/2 FORTITUDE™ Data Demonstrating Consistent Improvement Across Multiple Functional Measures Compared to Placebo in Del-Brax Treated FSHD Participants
News Preview
-- Unprecedented data from FORTITUDE™ dose escalation cohorts for del-brax treated participants, compared to placebo, demonstrate improvement in function, strength and PROs as well as rapid and significant reduction in biomarkers --
-- Data support planned accelerated approval BLA submission in H2 2026 --
-- Data being presented at the 32nd Annua...
Themefolio
Profiler
Peergroup
© PR Newswire
09.06.2025
RNA
LISTED
NASDAQ
Avidity Biosciences Announces the Accelerated Approval Regulatory Pathway in the U.S. is Open for Del-Brax and Initiates the Global, Confirmatory Phase 3 FORWARD™ Study in FSHD
News Preview
-- Planning accelerated approval BLA submission in H2 2026, following topline data fromFORTITUDE™ biomarker cohort in Q2 2026 --
-- Initiated global, confirmatory Phase 3 FORWARD™ study of del-brax 2mg/kg every six weeks --
-- Investor and analyst webcast event today, Monday, June 9, 2025 at 8 a.m. ET --
SAN DIEGO, June 9, 2025 /PRNewswire/ -- Av...
Themefolio
Profiler
Peergroup
© PR Newswire
21.05.2025
RNA
LISTED
NASDAQ
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
SAN DIEGO, May 21, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on May 20, 2025, the Human Capital Management Committee of Avidity's Board of Directors granted non-qualified...
Themefolio
Profiler
Peergroup
© PR Newswire
08.05.2025
RNA
LISTED
NASDAQ
Avidity Biosciences Reports First Quarter 2025 Financial Results and Recent Highlights
News Preview
On track to deliver key regulatory updates for del-brax and topline data from dose escalation cohorts in the FORTITUDE™ trial in the second quarter
Positive topline del-zota data further supports first BLA submission at year end 2025 – continues to highlight reproducibility and consistency across three late-stage clinical trials for DMD44, DM1 a...
Themefolio
Profiler
Peergroup
© PR Newswire
06.05.2025
RNA
LISTED
NASDAQ
Avidity Biosciences to Participate in Upcoming Investor Conference
News Preview
SAN DIEGO, May 6, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will participate in a fireside chat during the following investor conference:...
Themefolio
Profiler
Peergroup
© PR Newswire
21.04.2025
RNA
LISTED
NASDAQ
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
SAN DIEGO, April 21, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on April 20, 2025, the Human Capital Management Committee of Avidity's Board of Directors granted non-qualif...
Themefolio
Profiler
Peergroup
© PR Newswire
08.04.2025
RNA
LISTED
NASDAQ
Avidity Biosciences Receives Orphan Drug Designation in Japan for Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1
News Preview
Del-desiran first-ever investigational treatment for DM1 to receive Orphan Drug designation in Japan
SAN DIEGO, April 8, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that the Jap...
Themefolio
Profiler
Peergroup
© PR Newswire
01.04.2025
RNA
LISTED
NASDAQ
Avidity Biosciences to Participate in Upcoming Investor Conference
News Preview
SAN DIEGO, April 1, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will participate in a fireside chat during the following investor conference:...
Themefolio
Profiler
Peergroup
© PR Newswire
31.03.2025
RNA
LISTED
NASDAQ
Avidity Biosciences Completes Enrollment in Biomarker Cohort in Phase 1/2 FORTITUDE™ Trial for Delpacibart Braxlosiran (del-brax) in People Living with Facioscapulohumeral Muscular Dystrophy
News Preview
Del-brax FORTITUDE biomarker cohort designed for potential accelerated approval; plan to share regulatory update in Q2 2025
Regulatory alignment on global Phase 3 del-brax trial design and study initiation anticipated in Q2 2025
Plan to present topline data from FORTITUDE dose escalation cohorts in Q2 2025
On track to be first globally approved d...
Themefolio
Profiler
Peergroup
© PR Newswire
21.03.2025
RNA
LISTED
NASDAQ
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
SAN DIEGO, March 21, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on March 20, 2025, the Human Capital Management Committee of Avidity's Board of Directors granted non-qualif...
Themefolio
Profiler
Peergroup
© PR Newswire
17.03.2025
RNA
LISTED
NASDAQ
Avidity Biosciences Announces Positive Topline Del-zota Data Demonstrating Consistent, Statistically Significant Improvements in Dystrophin, Exon Skipping and Creatine Kinase in People Living with Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping i
News Preview
On track for year end 2025 BLA submission for accelerated approval of 5 mg/kg every six weeks of del-zota in DMD44
Consistent favorable safety and tolerability across del-zota dose cohorts
Plan to present functional data in fourth quarter of 2025
Investor and analyst webcast event today at 8:00 a.m. ET
SAN DIEGO, March 17, 2025 /PRNewswire/ -- A...
Themefolio
Profiler
Peergroup
© PR Newswire
12.03.2025
RNA
LISTED
NASDAQ
Avidity Biosciences Announces Upcoming Presentations at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
News Preview
Aravindhan Veerapandiyan, MD, Associate Professor of Pediatrics, University of Arkansas for Medical Sciences and Arkansas Children's Hospital and EXPLORE44® trial investigator, will present topline del-zota data from Phase 1/2 EXPLORE44 trial at 2025 MDA Clinical & Scientific Conference in Dallas, Texas
Avidity to host investor and analyst we...
Themefolio
Profiler
Peergroup
© PR Newswire
27.02.2025
RNA
LISTED
NASDAQ
Avidity Biosciences Reports Fourth Quarter 2024 Financial Results and Recent Highlights
News Preview
Building on success across its three clinical programs, Avidity is leading in rare neuromuscular diseases with a strong balance sheet to execute on a transformational 2025
Major milestones anticipated for each rare neuromuscular program in 2025, including preparing for Avidity's first BLA submission
Commercial preparations well underway in anti...
Themefolio
Profiler
Peergroup
© PR Newswire
25.02.2025
RNA
LISTED
NASDAQ
Avidity Biosciences to Participate in Upcoming Investor Conferences
News Preview
SAN DIEGO, Feb. 25, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will participate in a fireside chat during each of the following investor conferences:...
Themefolio
Profiler
Peergroup
© PR Newswire
21.02.2025
RNA
LISTED
NASDAQ
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
SAN DIEGO, Feb. 21, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on February 20, 2025, the Human Capital Management Committee of Avidity's Board of Directors granted non-qual...
Themefolio
Profiler
Peergroup
© PR Newswire
20.01.2025
RNA
LISTED
NASDAQ
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
SAN DIEGO, Jan. 20, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on January 20, 2025, the Human Capital Management Committee of Avidity's Board of Directors granted a non-qua...
Themefolio
Profiler
Peergroup
© PR Newswire
08.01.2025
RNA
LISTED
NASDAQ
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
SAN DIEGO, Jan. 8, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on January 6, 2025, the Human Capital Management Committee of Avidity's Board of Directors granted a non-quali...
Themefolio
Profiler
Peergroup
© PR Newswire
08.01.2025
RNA
LISTED
NASDAQ
Avidity Biosciences Plans First BLA Submission and Accelerates Commercialization Preparations for Three Rare Muscle Disease Programs in 2025
News Preview
Accelerated approval path confirmed for del-zota; Biologics License Application (BLA) submission planned for year end 2025
On track to complete enrollment in del-desiran HARBORTM Phase 3 and potential registrational del-brax biomarker cohort as well as initiate global pivotal trial for del-brax by mid-2025
Eric Mosbrooker expands role to Chi...
Themefolio
Profiler
Peergroup
© PR Newswire
20.12.2024
RNA
LISTED
NASDAQ
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
SAN DIEGO, Dec. 20, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on December 20, 2024, the Human Capital Management Committee of Avidity's Board of Directors granted non-qual...
Themefolio
Profiler
Peergroup
© PR Newswire
26.11.2024
RNA
LISTED
NASDAQ
Avidity Biosciences to Participate in Upcoming Investor Conference
News Preview
SAN DIEGO, Nov. 26, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will be participating in the following upcoming conference:...
Themefolio
Profiler
Peergroup
© PR Newswire
21.11.2024
RNA
LISTED
NASDAQ
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
SAN DIEGO, Nov. 21, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on November 20, 2024, the Human Capital Management Committee of Avidity's Board of Directors granted non-qual...
Themefolio
Profiler
Peergroup
© PR Newswire
12.11.2024
RNA
LISTED
NASDAQ
Avidity Biosciences Announces New Precision Cardiology Development Candidates to Treat Rare Genetic Cardiomyopathies and Provides First Look at Next-Generation Technology Innovations
News Preview
Avidity expands its leading RNA delivery technology into precision cardiology with two new wholly-owned development candidates targeting rare genetic cardiomyopathies: AOC 1086 to treat PLN Cardiomyopathy and AOC 1072 to treat PRKAG2 Syndrome
AOC 1072 and AOC 1086 preclinical data demonstrated robust siRNA delivery to the heart and targeted knoc...
Themefolio
Profiler
Peergroup
© PR Newswire
07.11.2024
RNA
LISTED
NASDAQ
Avidity Biosciences Reports Third Quarter 2024 Financial Results and Recent Highlights
News Preview
Enrollment in global Phase 3 HARBOR™ study for del-desiran in DM1 is on track
Avidity initiated biomarker cohort for del-brax FORTITUDE™ study for FSHD; pursuing a potential accelerated approval path for del-brax
Reported positive del-zota data from Phase 1/2 EXPLORE44™ trial for DMD44
Avidity to provide a first look at precision cardiology candi...
Themefolio
Profiler
Peergroup
© PR Newswire
31.10.2024
RNA
LISTED
NASDAQ
Avidity Biosciences to Host Investor and Analyst Event Focused on Precision Cardiology Candidates and First Look at Next-Generation Technology Innovations on November 12, 2024
News Preview
Avidity to present poster on precision cardiology candidate at American Heart Association (AHA) Scientific Sessions 2024 taking place November 16-18, 2024
Volume 11 of investor and analyst event series will be available via webcast November 12, 2024, at 8:00 a.m. ET
SAN DIEGO, Oct. 31, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA)...
Themefolio
Profiler
Peergroup
© PR Newswire
21.10.2024
RNA
LISTED
NASDAQ
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
SAN DIEGO, Oct. 21, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on October 20, 2024, the Human Capital Management Committee of Avidity's Board of Directors granted non-quali...
Themefolio
Profiler
Peergroup
© PR Newswire
03.10.2024
RNA
LISTED
NASDAQ
Avidity Biosciences Announces FDA Removed Partial Clinical Hold on Delpacibart Etedesiran (del-desiran/AOC 1001)
News Preview
SAN DIEGO, Oct. 3, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that the U.S. Food and Drug Administration (FDA) has removed the partial clinical hold on delpacibart etedesiran (d...
Themefolio
Profiler
Peergroup
© PR Newswire
25.09.2024
RNA
LISTED
NASDAQ
Avidity Biosciences to Participate in Upcoming Investor Conference
News Preview
SAN DIEGO, Sept. 25, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will be participating in the following upcoming conference:...
Themefolio
Profiler
Peergroup
© PR Newswire
23.09.2024
RNA
LISTED
NASDAQ
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
SAN DIEGO, Sept. 23, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on September 20, 2024, the Human Capital Management Committee of Avidity's Board of Directors granted non-qu...
Themefolio
Profiler
Peergroup
© PR Newswire
05.09.2024
RNA
LISTED
NASDAQ
Avidity Biosciences Joins Patient and Advocacy Communities in Raising Awareness During National Muscular Dystrophy Awareness Month
News Preview
Avidity supports World Duchenne Awareness Day, International Myotonic Dystrophy Awareness Day, FSHD Society Walk & Roll to Cure FSHD and Global Genes Week in RARE
Avidity reported groundbreaking data in all three clinical programs addressing rare muscular dystrophies: myotonic dystrophy type 1 (DM1), facioscapulohumeral muscular dystrophy (FS...
Themefolio
Profiler
Peergroup
© PR Newswire
28.08.2024
RNA
LISTED
NASDAQ
Avidity Biosciences to Participate in Upcoming Investor Conferences
News Preview
SAN DIEGO, Aug. 28, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will be participating in the following upcoming conferences:...
Themefolio
Profiler
Peergroup
© PR Newswire
21.08.2024
RNA
LISTED
NASDAQ
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
SAN DIEGO, Aug. 21, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on August 20, 2024, the Human Capital Management Committee of Avidity's Board of Directors granted non-qualif...
Themefolio
Profiler
Peergroup
© PR Newswire
19.08.2024
RNA
LISTED
NASDAQ
Avidity Biosciences Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
News Preview
SAN DIEGO, Aug. 19, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that it has closed its previously announced underwritten public offering of 8,418,000 shares of its common stock,...
Themefolio
Profiler
Peergroup
© PR Newswire
15.08.2024
RNA
LISTED
NASDAQ
Avidity Biosciences Announces Pricing of Upsized Public Offering of Common Stock
News Preview
SAN DIEGO, Aug. 14, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced the pricing of its upsized underwritten public offering of 7,320,000 shares of its common stock at a price to the...
Themefolio
Profiler
Peergroup
© PR Newswire
13.08.2024
RNA
LISTED
NASDAQ
Avidity Biosciences Announces Proposed Public Offering of Common Stock
News Preview
SAN DIEGO, Aug. 13, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that it intends to offer and sell, subject to market and other conditions, $250.0 million of shares of its common...
Themefolio
Profiler
Peergroup
© PR Newswire
09.08.2024
RNA
LISTED
NASDAQ
Avidity Biosciences Reports Second Quarter 2024 Financial Results and Recent Highlights
News Preview
Avidity reports positive del-zota (AOC 1044) data; demonstrated 25% increase in dystrophin production and reduction of creatine kinase levels to near normal in people living with DMD44 in Phase 1/2 EXPLORE44™ trial
Initiated global Phase 3 HARBOR™ trial and began administration of del-desiran in people living with DM1; del-desiran received FDA B...
Themefolio
Profiler
Peergroup
© PR Newswire
09.08.2024
RNA
LISTED
NASDAQ
Avidity Biosciences Announces Positive AOC 1044 Data Demonstrated Significant Increase of 25% in Dystrophin Production and Reduction of Creatine Kinase Levels to Near Normal in People Living with Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping in
News Preview
Delpacibart zotadirsen (AOC 1044) delivered unsurpassed muscle concentrations of PMO of 200 nM after three doses of 5 mg/kg
Statistically significant 37% increase in exon 44 skipping and up to 66% skipping with delpacibart zotadirsen 5 mg/kg at four months
Statistically significant increase of 25% of normal in dystrophin production and restored...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
